Test Directory
| Test Code | ||||||||||||||||||||||||||||||
| 1676 | ||||||||||||||||||||||||||||||
| Test Name | ||||||||||||||||||||||||||||||
| Torg-Winchester Syndrome | ||||||||||||||||||||||||||||||
| CPT Codes | ||||||||||||||||||||||||||||||
| 81479 | ||||||||||||||||||||||||||||||
| Expected Turnaround Time | ||||||||||||||||||||||||||||||
| Typically 2 to 4 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited. | ||||||||||||||||||||||||||||||
| Clinical Utility | ||||||||||||||||||||||||||||||
| Genetic analysis to provide a molecular diagnosis of this disorder. Recommended for individuals with a personal and/or family history of this disorder to ensure appropriate treatment and establish recurrence risk for family members. | ||||||||||||||||||||||||||||||
| Specimen and Container Info | ||||||||||||||||||||||||||||||
|
Non-Prenatal Specimens
Prenatal Specimens Either specimen type below is acceptable.
NOTE: For specimens from outside of North America, the preferred specimen type is Genomic DNA. HNL Genomics does not recommend shipping whole blood or cultured cells from any location other than the United States, Canada, or Mexico. |
||||||||||||||||||||||||||||||
| Transport Instructions | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Stability Requirements | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Causes for Rejection | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Methodology | ||||||||||||||||||||||||||||||
| Next Generation Sequencing and Copy Number Variation Analysis | ||||||||||||||||||||||||||||||
| Performing Location | ||||||||||||||||||||||||||||||
| Genomics - Snowdrift | ||||||||||||||||||||||||||||||
| Description | ||||||||||||||||||||||||||||||
|
Torg-Winchester syndrome (MIM 259600) is an autosomal recessive disorder. It was originally defined as three separate entities: Torg syndrome, Winchester syndrome and multicentric osteolysis with nodulosis and arthropathy (NOA syndrome). The 2006 revision of the Nosology of Constitutional Disorders of Bone classified Torg and Winchester syndromes as a single entity with NOA syndrome as a variant. Torg syndrome is characterized by a mild to moderate osteoporosis and osteolysis that is usually limited to the hands and feet. Widening of the metacarpal and metatarsal shafts, narrowing of the joints and erosions are seen. Contractures and progression involvement of other joints may occur. Another feature of Torg- syndrome is the presence of painless subcutaneous nodules. In Winchester syndrome there is severe osteolysis in the hands and feet and generalized osteoporosis. These patients do not have subcutaneous nodules. Facial dysmorphism, corneal opacities gum hypertrophy and EKG changes may be features. NOA syndrome patients display features of both Torg syndrome and Winchester syndrome. There is massive carpal and tarsal osteolysis, interphalangeal joint erosions with flexion contractures, generalized osteoporosis, facial dysmorphism, body hirsutism, and multiple painful plantar and palmar subcutaneous nodules. Torg-Winchester syndrome and NOA syndrome are caused by loss of function mutations in the matrix metalloproteinase 2 gene (MMP2). This gene encodes type IV collagenase also known as gelatinase A. |
||||||||||||||||||||||||||||||
| Testing Schedule | ||||||||||||||||||||||||||||||
| Monday-Friday | ||||||||||||||||||||||||||||||
| Genes | ||||||||||||||||||||||||||||||
| MMP2 | ||||||||||||||||||||||||||||||
| MIM | ||||||||||||||||||||||||||||||
| 259600 | ||||||||||||||||||||||||||||||
| Disease Group | ||||||||||||||||||||||||||||||
| Skeletal Disorders | ||||||||||||||||||||||||||||||
The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. View the Terms.
© 2026 HNL Lab Medicine. All rights reserved.